advanced and/or recurrent gastric cancer
Conditions
Interventions
S-1 is orally administered for 21 days followed by 14 days rest according to body surface area. CDDP is administered intravenously in each dosage of level at day 8 .
Sponsors
NPO Japan Southwest Oncology Research Support Organization (JSWOG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proven adenocarcinoma of advanced gastric cancer(included esophagogastric junction) 2)CDDP-naïve patients 3)ECOG Performance status(PS) of 0-1. 4)Age of 20 years or older. 5 ) Life expectancy is less than 3 months 6)no severe organ failure 7) possible to oral intake 8) written informed consent
Exclusion criteria
Exclusion criteria: (1) Patient with administration contraindication of S-1 or CDDP (2,3,4,5) pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, ileus, uncontrollable diabetes, hypertension, renal failure, hepatic cirrhosis, active interstitial. (6) Symptomatic pleural effusion or ascites (7) metastasis to the brain (8) Watery diarrhea (9) Symptomatic psychological disease (10)Concomitant therapy with flucytocine or phenytoin (11)Pregnancy or breast feeding (12)Decision as ineligible by principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactTomoki Yamatsuji
Kawasaki Medical School Department of General Surgery
Outcome results
None listed